Evidence map›Paper›PMID 38449865›Full record

ArticleFrontiers in immunology2024

Corrigendum: Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence.

Lorenzo Federico, Brandon Malone, Simen Tennøe, Viktoriia Chaban, Julie Røkke Osen, Murat Gainullin, Eva Smorodina, Hassen Kared, Rahmad Akbar, Victor Greiff and 3 more

Open access · goldAbstract readPublished Erratum
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Lorenzo FedericoDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Brandon MaloneNEC OncoImmunity AS, Oslo, Norway.
Simen TennøeNEC OncoImmunity AS, Oslo, Norway.
Viktoriia ChabanDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Julie Røkke OsenDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Murat GainullinDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Eva SmorodinaDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Hassen KaredDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Rahmad AkbarDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Victor GreiffDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Richard StratfordNEC OncoImmunity AS, Oslo, Norway.
Trevor ClancyNEC OncoImmunity AS, Oslo, Norway.
Ludvig Andre MuntheDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Oslo University Hospital · NOUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2023.1265044.].

Indexed as

antigen (Ag)artificial intelligenceCD4+ lymphocytesCD8+ lymphocytesCOVID-19SARS-CoV-2T cellvaccine

Identifiers

PMID38449865
PMCPMC10916508
OpenAlexW4392012930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.